$ALMS

Bradley Mark Christopher sold $68K of ALMS

Bradley Mark Christopher (Chief Development Officer) sold 2,572 shares of ALUMIS INC. (ALMS) at $26.37 on 2026-08-03.

Original reporting
SEC EDGAR · Bradley Mark Christopher
Published Aug 5, 2026, 10:21 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 5, 2026, 11:02 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$ALMS
Neutral
low confidence
Mentioned
$ALMS
Relevance
3/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$ALMSNeutralLow
01

Why it matters

The newest fact is the specific open-market sale details by the named officer, including price, shares, and post-transaction holdings.

02

Market read

Traders may note insider selling, but the filing alone is usually not a standalone catalyst for repricing.

03

What to watch

The article does not provide context for the sale (taxes, scheduled liquidity needs, or prior grants), so interpreting it as a strong signal is risky.

Relevance 3/10Novelty 3/10Timing: filed 2026-08-05 after-hours; transaction dated 2026-08-03

Background

The article is a SEC Form 4 insider transaction disclosure for ALUMIS INC. (ALMS).

Company-level read

Ticker impact

$ALMSNeutralLow confidence
Context

ALMS disclosed an insider open-market sale by its Chief Development Officer of 2,572 shares at $26.37 on 2026-08-03.

Expected impact

Likely limited near-term impact; any reaction would be sentiment-driven and typically fades unless accompanied by other company-specific news.

Evidence & confidence

The filing provides transaction size, price, and post-sale holdings, but no accompanying guidance, operational update, or enforcement/regulatory action.

Market effects

Minimal, as this is company-specific insider trading with no sector-wide signal.

None indicated.

None indicated.

Counterpoint

Insider sales can be planned for liquidity or diversification; the absence of a stated 10b5-1 plan does not automatically imply bearish information.

Key entities

  • ALUMIS INC.

    Subject of the Form 4 insider transaction disclosure.

  • Bradley Mark Christopher

    Chief Development Officer who sold 2,572 shares.

Related articles

$ALMSMedAI 9/10

Analyst Sentiment On Alumis (ALMS) Remains Strong Following Q1 Results And Envudeucitinib Pipeline Advancements

Alumis Inc. (ALMS) shares drew three analyst price-target raises after its Q1 2026 results and progress on envudeucitinib. Chardan lifted its target to $40 from $38 (Buy), Wells Fargo to $51 from $49 (Overweight), and Guggenheim to $34 from $32 (Buy). The company reported $569.5M cash and narrowed net loss to $93.1M; envudeucitinib Week 24 PASI 90/100 results were also cited.